Lipid Panel Guide: LDL, HDL, Triglycerides Explained

What a lipid panel actually measures

A standard lipid panel measures four core quantities: total cholesterol, LDL (low-density lipoprotein cholesterol), HDL (high-density lipoprotein cholesterol), and triglycerides. Most modern laboratory reports also calculate non-HDL cholesterol (total cholesterol minus HDL), which several bodies — including the UK's NICE and the American Heart Association — now regard as a stronger, more robust predictor of cardiovascular events than LDL measured alone. Increasingly, panels add apolipoprotein B (ApoB) and sometimes lipoprotein(a), or Lp(a), for a more complete picture of the particles actually doing the damage.

The reason a lipid panel exists is deceptively simple: atherosclerotic cardiovascular disease (ASCVD) — heart attacks, most strokes, and peripheral artery disease — remains the leading cause of death worldwide, according to the World Health Organization. The disease is silent for decades while cholesterol-carrying particles quietly build plaque inside artery walls. A lipid panel is the cheapest, most widely available window we have into that process before it becomes a symptom. You can browse each of these markers individually in our biomarker library, but the clinical value comes from reading them together.

One important caveat sets the tone for everything below: no single number on this panel decides anything. A person with an LDL of 160 mg/dL and no other risk factors may need only lifestyle changes, while another with an LDL of 90 mg/dL, diabetes, high blood pressure, and a family history of early heart attacks may warrant medication. Context is the whole game, and it is exactly where both good clinicians and good AI analyzers earn their keep.

The biology: how cholesterol travels in blood

Cholesterol is not a villain; it is essential. Every cell membrane in your body contains it, and it is the raw material for vitamin D, bile acids, cortisol, testosterone, and estrogen. The problem is not cholesterol itself but the way excess quantities of it are transported and where they end up.

Because cholesterol and triglycerides are fats, they cannot dissolve in the watery bloodstream. To move around, they are packaged inside lipoproteins — spherical particles with a fatty core and a water-friendly protein-and-phospholipid shell. The lipid panel is essentially a census of these particles, sorted by density:

• Chylomicrons — the largest, made in the gut after a meal, carrying dietary triglycerides. They are the main reason a non-fasting sample can show high triglycerides.
• VLDL (very-low-density lipoprotein) — made by the liver, triglyceride-rich. On a standard panel, VLDL is estimated as triglycerides divided by 5.
• LDL (low-density lipoprotein) — what remains after VLDL sheds its triglycerides. This is the classic 'bad cholesterol' that infiltrates artery walls.
• HDL (high-density lipoprotein) — the smallest and densest, involved in returning cholesterol from tissues to the liver.
• Lp(a) — an LDL-like particle with an extra protein tail; largely genetically determined and strongly atherogenic when elevated.

Here is the mechanism that makes LDL dangerous. When LDL particles are numerous, some cross the thin single-cell lining of the artery (the endothelium) and become trapped in the wall. There they oxidize, triggering an immune response: white blood cells engulf the cholesterol, swell into 'foam cells', and form a fatty streak. Over years this becomes a plaque with a lipid core and a fibrous cap. If the cap ruptures, the body clots over it — and that clot, in a coronary artery, is a heart attack. This is why the field increasingly emphasizes the number of atherogenic particles (best reflected by ApoB and non-HDL) rather than just the mass of cholesterol they carry.

LDL: the primary driver of plaque

LDL cholesterol is the fraction most consistently and causally linked to atherosclerosis. The evidence is overwhelming: Mendelian randomization studies (which use lifelong genetic differences in LDL as a natural experiment), decades of statin and ezetimibe trials, and the newer PCSK9-inhibitor trials all point the same way — lower LDL, lower risk, in a dose-dependent fashion, with no clear floor. The European Society of Cardiology (ESC) and the American Heart Association/American College of Cardiology (AHA/ACC) both frame LDL as the primary target of cholesterol-lowering therapy. You can read the standalone entry for this marker at /biomarkers/ldl/.

Targets are risk-stratified rather than one-size-fits-all. The lower your background risk, the more relaxed the target; the higher your risk, the more aggressive it becomes:

How is LDL derived? Historically it was calculated, not measured, using the Friedewald equation: LDL = total cholesterol − HDL − (triglycerides ÷ 5). This estimate becomes unreliable when triglycerides exceed roughly 400 mg/dL or when LDL is very low, so many laboratories have switched to the more accurate Martin-Hopkins equation or a direct LDL assay. If your LDL looks implausibly low next to a high triglyceride reading, a calculation artifact is a likely culprit — a nuance a good analyzer flags automatically.

Very high LDL — particularly readings above 190 mg/dL in an adult, or a strong family history of early heart disease — raises the question of familial hypercholesterolemia (FH), a common inherited condition (roughly 1 in 250 people) in which the liver clears LDL poorly from birth. FH substantially raises lifelong risk and often warrants earlier, more aggressive treatment and family (cascade) screening, a point emphasized by the NIH's National Heart, Lung, and Blood Institute (NHLBI).

HDL: protective, but not always

HDL carries cholesterol away from tissues — including artery walls — back to the liver for recycling or disposal, a process called reverse cholesterol transport. Epidemiologically, higher HDL has long been associated with lower cardiovascular risk, which earned it the nickname 'good cholesterol.' The reference thresholds still used by most laboratories reflect this: at least 40 mg/dL for men and at least 50 mg/dL for women is considered adequate, with values around 60 mg/dL traditionally viewed as favorable. See /biomarkers/hdl/ for the marker detail.

But HDL turned out to be more complicated than the nickname suggests, and this is one of the most important updates in modern lipidology. Two lines of evidence reshaped thinking:

• Drug trials failed. Medications (CETP inhibitors like torcetrapib and dalcetrapib, and high-dose niacin) that raised HDL substantially did not reduce cardiovascular events, and some caused harm. Raising the number did not deliver the benefit the association predicted.
• The curve is U-shaped, not a straight line. Large cohort analyses found that very high HDL — roughly above 80-90 mg/dL — is associated with higher, not lower, mortality in some populations, sometimes tied to specific genetic variants that produce dysfunctional HDL.

The current interpretation: HDL is best read as a marker of risk, not a lever to pull. A low HDL flags metabolic problems (insulin resistance, inactivity, smoking, obesity) that themselves drive risk; a very high HDL is not a badge of extra protection and occasionally signals a problem. This is why the original observation in this guide holds — HDL above roughly 90 mg/dL confers no additional benefit and may even be unfavorable in some genetic subtypes. The practical takeaway is to improve HDL indirectly through exercise, weight management, and not smoking, while focusing treatment on lowering the atherogenic particles.

Triglycerides and metabolic health

Triglycerides are the storage and transport form of fat, ferried mainly by chylomicrons and VLDL. Because they respond quickly to recent meals, alcohol, and carbohydrate intake, triglycerides are the most volatile number on the panel — and one of the most informative about metabolic health. The standard threshold, echoed by the AHA and ESC, is below 150 mg/dL. The full marker entry lives at /biomarkers/triglycerides/.

Elevated triglycerides matter for two separate reasons. First, they are a signal: values above 150 mg/dL typically reflect refined-carbohydrate or alcohol intake, excess weight, or — most importantly — insulin resistance, the metabolic state that precedes type 2 diabetes. A rising triglyceride level alongside a falling HDL is a classic fingerprint of metabolic syndrome. Second, at extreme levels triglycerides become a direct danger: above roughly 500 mg/dL the risk of acute pancreatitis climbs, and above 880 mg/dL (10 mmol/L) it becomes a genuine emergency requiring urgent treatment.

Because triglycerides feed the insulin-resistance story, they connect directly to blood sugar. If your triglycerides are high, your fasting glucose and HbA1c deserve a look too — our companion guide, HbA1c explained, covers how the three-month average glucose fits the same metabolic picture. The American Diabetes Association (ADA) treats this cluster of triglycerides, glucose, waist circumference, blood pressure, and HDL as the recognizable pattern of metabolic syndrome.

Non-HDL and ApoB: what 2026 guidelines prioritize

If there is one shift that separates a modern lipid interpretation from a 1990s one, it is the move away from LDL-in-isolation toward non-HDL cholesterol and ApoB. Both capture something LDL alone misses: the total burden of atherogenic particles, including the triglyceride-rich remnants (VLDL and its leftovers) that also drive plaque.

Non-HDL cholesterol is trivially easy to compute — total cholesterol minus HDL — and requires no extra blood draw or fasting. It sums the cholesterol carried by every atherogenic particle (LDL + VLDL + Lp(a) + remnants). NICE in the UK explicitly favors non-HDL over LDL for risk assessment and treatment monitoring, and the AHA regards it as a superior predictor, especially when triglycerides are elevated and LDL calculations wobble. A practical rule of thumb: the non-HDL target is roughly 30 mg/dL higher than the corresponding LDL target (so below 130 where the LDL goal is below 100, below 100 where LDL is below 70, and so on).

ApoB goes one step further. Because each atherogenic particle carries exactly one ApoB molecule, measuring ApoB is effectively a direct particle count. When ApoB and LDL disagree — most often in people with high triglycerides, diabetes, or obesity, where LDL underestimates the true particle number — ApoB is the more reliable guide to risk. The ESC lists ApoB as a valid alternative measurement target, and many lipid specialists now consider it the single best routine lipid marker available.

Ratios and derived markers

Several ratios squeeze extra signal out of the same four numbers, and they are often more stable and more predictive than any single value:

• Total cholesterol / HDL ratio — a compact summary of overall lipid risk. Below about 3.5 is favorable; above 5 is concerning. It is one of the inputs to several risk calculators.
• TG / HDL ratio — one of the simplest widely available proxies for insulin resistance and small, dense LDL. In conventional mg/dL units, a ratio above roughly 3-3.5 suggests insulin resistance, particularly in people of European ancestry (the threshold differs by population).
• LDL / HDL ratio — an older summary metric, largely superseded by non-HDL and ApoB but still reported by some labs.
• Non-HDL / HDL and ApoB / ApoA1 — refinements used in specialist settings.

Ratios are useful precisely because they combine an atherogenic numerator with a protective denominator, dampening some of the day-to-day noise in the raw values. They are still summaries, though — a good analysis reports the ratio and the components, so you can see whether a high TC/HDL ratio is driven by high LDL, low HDL, or both, because the fix differs in each case.

Reference ranges and targets at a glance

The table below consolidates the conventional laboratory reference ranges (the values printed on most reports) alongside the risk-based treatment targets discussed above. Reference ranges describe a 'desirable' population distribution; treatment targets are personalized to your risk and set by a clinician. The two are not the same thing, and confusing them is a common source of unnecessary worry — or false reassurance.

A note on units: the United States reports cholesterol in mg/dL; most of Europe, the UK, Canada, and Australia use mmol/L. To convert cholesterol values, divide mg/dL by 38.67 (so LDL 100 mg/dL is about 2.6 mmol/L). Triglycerides convert differently — divide mg/dL by 88.57. The International Federation of Clinical Chemistry (IFCC) standardizes these assays so results are comparable across accredited labs, and reference-range harmonization efforts such as NORIP (the Nordic Reference Interval Project) and pediatric work like CALIPER underpin the ranges you see. A quality analyzer detects your unit automatically and converts as needed.

What pushes each number up or down

Lipids are not shaped by diet alone. Genetics, thyroid function, kidney and liver health, medications, pregnancy, and other conditions all move the numbers — which is why an out-of-range result is a starting question, not a conclusion. The table summarizes the common drivers; note how often a single underlying condition, such as hypothyroidism, disturbs several values at once.

Two points deserve emphasis. First, hypothyroidism raises LDL and triglycerides and is a classic reversible cause of a 'bad' lipid panel — which is why clinicians often check thyroid function before starting cholesterol medication. Our thyroid panel guide explains how TSH and free T4 fit in. Second, the liver manufactures and clears lipoproteins, so liver disease can disturb the panel in either direction; if liver enzymes are also abnormal, our liver function tests guide is the natural next read. These cross-connections are exactly what a whole-panel interpretation is designed to surface.

10-year cardiovascular risk in 2026

A single lipid number does not decide anything — the integrated risk estimate does. Rather than asking 'is my LDL high?', modern practice asks 'what is my probability of a heart attack or stroke over the next 10 years, given all my risk factors?' That question is answered by validated calculators that combine lipids with age, sex, blood pressure, smoking status, and diabetes.

In the United States, two tools dominate. The long-standing Pooled Cohort Equations (ASCVD Risk Estimator) from the AHA/ACC estimates 10-year risk of a first heart attack or stroke; broadly, under 5% is low, 5-7.5% is borderline, 7.5-20% is intermediate, and 20% or more is high. In 2023-2024 the AHA introduced the newer PREVENT equations, which add kidney function and metabolic factors and can also estimate 30-year risk — a meaningful advance for younger adults whose 10-year number looks low but whose lifetime trajectory does not. In Europe the ESC uses SCORE2 and SCORE2-OP (for older people), and the UK's NICE uses QRISK. The U.S. Preventive Services Task Force (USPSTF) frames who should even be screened and considered for a statin.

When the risk estimate lands in a grey zone, clinicians increasingly reach for 'risk-enhancing' factors and additional tests to reclassify the patient: a high Lp(a), a strong family history of premature disease, elevated hs-CRP (a marker of inflammation), South Asian ancestry, chronic inflammatory conditions, or a coronary artery calcium (CAC) score from a low-dose CT — which directly visualizes plaque and is one of the most powerful reclassifiers available. A CAC of zero can safely defer medication in some intermediate-risk patients; a high score argues for treatment.

How a lipid panel is measured

A lipid panel runs on a small venous blood sample, usually a few milliliters drawn from the arm into a tube with no anticoagulant or with a specific additive, then spun down to serum or plasma. In the analyzer, cholesterol and triglycerides are measured by enzymatic colorimetric assays — a cascade of enzymes produces a colored product whose intensity is proportional to the concentration. HDL is measured after selectively blocking or precipitating the other lipoproteins so only HDL cholesterol is read.

Several factors affect accuracy and are worth knowing before you over-interpret a single result:

• Biological variability. Your true lipid levels fluctuate day to day; LDL can vary by roughly 5-10% between draws even under identical conditions. A single borderline result is best confirmed with a repeat.
• Recent illness. Acute infection, surgery, or a recent heart attack can transiently lower cholesterol for weeks — a panel taken during hospitalization for a cardiac event may understate your baseline.
• Posture and tourniquet. Prolonged standing or a tight, prolonged tourniquet can modestly raise measured values through hemoconcentration.
• Calculation artifacts. When triglycerides are very high, the Friedewald-calculated LDL becomes unreliable, and labs should switch to a direct assay or the Martin-Hopkins method.
• Assay standardization. Accredited labs are traceable to IFCC reference methods, so results are broadly comparable — but small differences between platforms exist, so trend within one lab where possible.

This is why trends beat snapshots. Two panels three months apart tell a far richer story than one, especially when you are testing the effect of a diet change or a new medication.

Fasting, timing, and test prep

For years, patients were told to fast for 9-12 hours before any lipid test. That advice has relaxed. Both the ESC and a 2016 joint European consensus concluded that routine lipid screening does not require fasting, because total cholesterol, HDL, non-HDL, and LDL change only trivially after a meal. Non-fasting panels are now standard for screening in much of the world, and they make testing far more convenient.

The exception is triglycerides, which rise after eating. If your triglycerides are being specifically tracked — for pancreatitis risk, for tuning treatment, or because a prior non-fasting value was high — a 12-hour fast gives the cleanest comparison. Practical preparation:

• Avoid alcohol for 24 hours before a triglyceride-focused draw — a single heavy night can spike them dramatically.
• Don't dramatically change your diet in the days before the test; you want a representative reading, not a best-case one.
• Stay hydrated with water; dehydration concentrates the sample.
• Take your regular medications unless your clinician says otherwise, and tell the lab what you take.
• Try to test under similar conditions each time (same lab, similar time of day) so trends are meaningful.

Related conditions and secondary causes

An abnormal lipid panel is sometimes the first clue to a condition that has nothing to do with diet. Clinicians call these 'secondary causes,' and finding one can change management entirely — treat the underlying problem and the lipids often normalize. Key examples:

• Hypothyroidism — raises LDL and triglycerides; correcting thyroid hormone can substantially improve the panel, per American Thyroid Association guidance.
• Type 2 diabetes and insulin resistance — produce the classic 'diabetic dyslipidemia' of high triglycerides, low HDL, and small dense LDL, even when LDL cholesterol looks unremarkable (a reason to check ApoB).
• Chronic kidney disease and nephrotic syndrome — nephrotic syndrome in particular can cause strikingly high cholesterol.
• Liver and biliary disease — cholestasis raises cholesterol; advanced liver disease can lower it.
• Pregnancy — cholesterol and triglycerides rise normally and should not be interpreted with standard thresholds.
• Medications — corticosteroids, some diuretics and beta-blockers, certain antiretrovirals, atypical antipsychotics, and estrogens can all shift lipids.
• Familial dyslipidemias — inherited disorders (familial hypercholesterolemia, familial combined hyperlipidemia) that warrant family screening and earlier treatment, flagged by the Endocrine Society and NHLBI.

Because these conditions ripple across many markers, they are best caught by reading the whole report together — glucose, thyroid, kidney (eGFR, creatinine), and liver panels alongside the lipids. That whole-panel pattern-matching is precisely what a well-built analyzer does in seconds and what a rushed appointment sometimes misses.

How an AI analyzer reads your lipids in context

When you upload a lipid panel to blood-test.life, the Kantesti AI engine does not simply color each value red or green against a reference range. It reconstructs the reasoning an experienced clinician would apply. In practice that means:

1. Extract and normalize. It reads every value off your report — even messy PDFs and photos — detects whether you are in mg/dL or mmol/L, and converts consistently.
2. Compute the derived markers. Non-HDL, the TC/HDL and TG/HDL ratios, and, where the data allow, an estimate of atherogenic burden — so you see the numbers your lab may not have printed.
3. Apply the right guideline targets. It uses the risk-stratified LDL and non-HDL targets from AHA/ACC and ESC rather than treating the population reference range as a goal.
4. Run the risk calculators. When you provide age, blood pressure, smoking, and diabetes status, it applies the ASCVD/PREVENT-style logic to produce a 10-year risk estimate alongside the raw values.
5. Cross-reference the whole panel. It checks whether a high LDL sits next to a high TSH (possible hypothyroidism), whether high triglycerides pair with a high HbA1c (insulin resistance), or whether a lipid calculation looks like an artifact — connections a single-number view would miss.
6. Explain in plain language. It translates the pattern into readable guidance and points you to what to discuss with a clinician.

The mechanics of that pipeline are described in our how it works page, and you can compare plans on the pricing page. The critical honesty here: this is educational analysis, not a diagnosis, and blood-test.life is not a regulated medical device. It is built to help you understand your results and ask better questions — not to replace the clinician who can examine you, order confirmatory tests, and prescribe treatment.

When to see a clinician

Some findings warrant a routine conversation; a few warrant prompt or urgent attention. As general guidance — not a substitute for individual medical advice:

• Book a routine visit if your LDL or non-HDL is persistently above the desirable range, if your triglycerides sit in the 150-499 range, or if you have several risk factors (family history, smoking, high blood pressure, diabetes).
• Seek prompt review if your LDL is above 190 mg/dL, or if there is a family history of heart attacks before age 55 in men or 65 in women — both raise the question of familial hypercholesterolemia.
• Treat as urgent if triglycerides are above 500 mg/dL (pancreatitis risk), and especially above ~880 mg/dL.
• Call emergency services immediately — do not wait for a blood test — for symptoms of a heart attack or stroke: chest pressure, pain spreading to the arm or jaw, sudden shortness of breath, face drooping, arm weakness, or slurred speech.

Bring your actual numbers and, ideally, prior results so your clinician can see the trend. If you have used an AI analysis, bring that summary as a conversation starter — but let the clinician's assessment, informed by your history and examination, guide any treatment.

Lowering risk: evidence-based next steps

Lifestyle changes are the foundation of cardiovascular risk reduction for everyone, and for many lower-risk people they are sufficient on their own. The measures with the strongest evidence, endorsed across AHA, ESC, and WHO guidance:

• Replace saturated and trans fats with unsaturated fats. Swapping butter, fatty processed meats, and fried foods for olive oil, nuts, seeds, and oily fish lowers LDL. A Mediterranean-style pattern has the best trial evidence.
• Cut refined carbohydrates and added sugar. This is the single most effective dietary lever for high triglycerides and often raises HDL indirectly.
• Add soluble fiber. Oats, legumes, and psyllium bind bile acids and modestly lower LDL.
• Move regularly. At least 150 minutes per week of moderate aerobic activity improves triglycerides, HDL, blood pressure, and insulin sensitivity.
• Reach and hold a healthier weight. Even a 5-10% loss meaningfully improves triglycerides and HDL.
• Limit alcohol. It is a major and often overlooked driver of high triglycerides.
• Stop smoking. Smoking lowers HDL and damages the artery lining directly; quitting is among the highest-impact changes possible.
• Consider medication when indicated. Statins are first-line and among the best-evidenced drugs in all of medicine; ezetimibe, PCSK9 inhibitors, bempedoic acid, and icosapent ethyl (for high triglycerides) extend the toolkit. These are clinician decisions.

Retest after a meaningful interval — typically about 8-12 weeks after a diet change or a new medication — to see whether the change worked. This is where tracking a trend, rather than obsessing over one draw, pays off. If you want the fuller preventive-health picture, our library at /biomarkers/ and the guides at /learn/hba1c-explained/ connect lipids to the rest of your metabolic panel.

Common cholesterol myths

Few blood tests attract more misinformation than the lipid panel. A few persistent myths, corrected:

• 'Dietary cholesterol is the main driver of blood cholesterol.' For most people, saturated and trans fats raise LDL far more than dietary cholesterol itself; eggs, for instance, affect most people's LDL modestly.
• 'High HDL cancels out high LDL.' It does not. A favorable HDL does not neutralize the risk from a high atherogenic particle burden — you still treat the LDL/ApoB.
• 'If my total cholesterol is normal, I'm fine.' Total cholesterol can look normal while LDL is high and HDL is low, or while triglycerides are dangerous. Total cholesterol is a starting point, never a verdict.
• 'Statins are dangerous / cause memory loss.' Large trials show statins are safe and highly effective for the right patients; serious side effects are rare, and the muscle aches sometimes attributed to them frequently occur on placebo too.
• 'Cholesterol is bad and lower is always better for everyone.' Cholesterol is essential; the goal is appropriate LDL/ApoB for your risk, not zero, and unusually low values can occasionally reflect illness or malnutrition.
• 'Thin people don't need to worry.' Familial hypercholesterolemia and high Lp(a) affect people of any body size; genetics, not just weight, drive lipid risk.

Questions patients actually ask

A few recurring questions that don't fit neatly elsewhere. As always, these are general explanations — your clinician's advice, tailored to you, takes precedence.

My LDL went up but I didn't change anything — why?

Lipids have real biological variability (roughly 5-10% for LDL between draws), and factors like a recent illness, a different lab, seasonal changes, weight shifts, thyroid changes, or even how long the tourniquet was on can move the number. One reading rarely tells the whole story; confirm with a repeat before concluding anything.

Do I need ApoB or Lp(a) if my standard panel is normal?

Often yes, at least once. ApoB can reveal a high particle count hidden behind a normal-looking LDL, especially with high triglycerides or diabetes, and Lp(a) uncovers a genetic risk that a standard panel never shows. Many specialists recommend a one-time Lp(a) for every adult.

Can I lower cholesterol without medication?

Many people can meaningfully improve their panel — especially triglycerides and HDL — through diet, exercise, weight loss, and quitting smoking, and for lower-risk individuals that may be all that's needed. But some causes (familial hypercholesterolemia, high Lp(a), established heart disease) usually require medication regardless of lifestyle. It is a shared decision with your clinician based on your overall risk.

Frequently asked questions